Popular Trials
Thromboxane A2 Receptor Antagonist
Oral Ifetroban for Scleroderma
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Phosphodiesterase-5 (PDE-5) Inhibitor
Inhaled Vardenafil for Pulmonary Arterial Hypertension
This trial is testing an inhaled medication called RT234. It aims to help people with pulmonary arterial hypertension (PAH) breathe better and exercise more easily. The medication works by widening the blood vessels in the lungs, making it easier for the heart to pump blood. RT234 is being developed to improve exercise tolerance and symptoms in patients with PAH.
Behavioural Intervention
Home-based rehabilitation for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension has gone from a disease that causes rapid death to a more chronic condition. Yet, improved survival is associated with major challenges for clinicians as most patients remain with poor quality of life and limited exercise capacity. The effects of exercise training on exercise capacity have been largely evaluated and showed an improvement in 6-minutes walking distance (6MWD), peak V'O2. It is also known that exercise program improves quality of life. Maximal volitional and nonvolitional strength of the quadriceps are reduced in patients with Pulmonary Arterial Hypertension and correlated to exercise capacity. Moreover, on the cellular level, alterations are observed in both the respiratory as well as the peripheral muscles. Muscle fiber size has been reported to be decreased in some studies or conversely unaltered in human and animal models. Reduction in type I fibers and a more anaerobic energy metabolism has also been reported, but not in all studies. Likewise, a loss in capillary density in quadriceps of patients with Pulmonary Arterial Hypertension and rats has been reported, but could not be confirmed in other studies. While the impact of exercise training on clinical outcomes such as exercise capacity or quality of life is well known, this data highlight the fact that the underlying causes of peripheral muscle weakness as well as the mechanisms underlying the clinical improvements observed with exercise programs are not completely understood. Improvement of muscle cell metabolism in part via the enhancement of oxidative cellular metabolism and decrease in intracellular lipid accumulation may play a role in improving muscle function and exercise capacity. In this study, we intend to evaluate the impact of a 12 weeks home-based rehabilitation program on peripheral muscle function and metabolism, focusing on lipid infiltration, oxidative metabolism and epigenetic factors that can be involved in metabolic syndrome, in patients with Pulmonary Arterial Hypertension.
Procedure
Temporary right ventricular pacing for Right Ventricular Dysfunction
This trial will study if and how RV pacing can help people with PAH by looking at electrical activation in the RV, mapping the area of latest activation, and then evaluating the hemodynamic and energetic effects of RV pacing in these patients.
Biguanides
Metformin + mHealth for Pulmonary Arterial Hypertension
This trial is testing two interventions to see if they can improve insulin resistance in people with pulmonary artery hypertension. The primary endpoint is a 10% improvement in the distance the person can walk in six minutes, or an improvement in the person's functional class according to the World Health Organization.
Popular Filters
Trials for PAH Patients
Morphine sulfate - Visit 1 for Pulmonary Arterial Hypertension
Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic. In one survey of 315 patients with PAH, sixty-eight percent had moderate or severe dyspnea on exertion and 40% had a profound and clinically significant deficit in quality of life. Palliative care is being increasingly investigated in life-limiting cardiovascular diseases to alleviate symptoms. In PAH, its implementation is frequently delayed until end-of-life. Opioids are a common palliative care intervention, however the efficacy and safety of opioids for symptom relief in PAH has not been evaluated.
Vascular Function in Pulmonary Arterial Hypertension
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
Trials for PH Patients
Aldosterone Receptor Antagonist
Spironolactone for Pulmonary Hypertension
The purpose of this study is to determine the effects of spironolactone on collagen markers in a large number of patients with pulmonary hypertension. In addition, safety and tolerability of spironolactone, an aldosterone receptor antagonist, in patients with pulmonary arterial hypertension, will be determined.
Endothelin Receptor Antagonist
Bosentan for Pulmonary Hypertension
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal hemodynamics at rest. The authors hypothesize that early treatment may change the course of disease progression by improving hemodynamics during exercise, thus delaying disease progression.
Device
Aria CV System for Pulmonary Arterial Hypertension
This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
Phase 3 Trials
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
Endothelin Receptor Antagonist
Bosentan for Pulmonary Hypertension
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal hemodynamics at rest. The authors hypothesize that early treatment may change the course of disease progression by improving hemodynamics during exercise, thus delaying disease progression.
Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor
Macitentan + Tadalafil Combination for Pulmonary Arterial Hypertension
This trial will compare the efficacy of a fixed-dose combination of macitentan and tadalafil to that of macitentan or tadalafil given alone in patients with pulmonary arterial hypertension.
Trials With No Placebo
Morphine sulfate - Visit 1 for Pulmonary Arterial Hypertension
Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic. In one survey of 315 patients with PAH, sixty-eight percent had moderate or severe dyspnea on exertion and 40% had a profound and clinically significant deficit in quality of life. Palliative care is being increasingly investigated in life-limiting cardiovascular diseases to alleviate symptoms. In PAH, its implementation is frequently delayed until end-of-life. Opioids are a common palliative care intervention, however the efficacy and safety of opioids for symptom relief in PAH has not been evaluated.
Vascular Function in Pulmonary Arterial Hypertension
This trial is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease.
Endothelin Receptor Antagonist
Macitentan for Pulmonary Hypertension
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
Endothelin Receptor Antagonist
Bosentan for Pulmonary Hypertension
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal hemodynamics at rest. The authors hypothesize that early treatment may change the course of disease progression by improving hemodynamics during exercise, thus delaying disease progression.
View More Related Trials
Frequently Asked Questions
Introduction to pulmonary arterial hypertension
What are the top hospitals conducting pulmonary arterial hypertension research?
When it comes to cutting-edge clinical trials in the field of pulmonary arterial hypertension, several top hospitals are leading the way. In Saint Louis, Washington University School of Medicine is at the forefront with seven ongoing trials focused on this condition. This renowned institution is dedicated to pushing the boundaries of knowledge and treatment for pulmonary arterial hypertension. Similarly, Duke University Medical Center in Durham has also embarked on seven active clinical trials in pursuit of better therapies for this challenging disease. With a reputation for excellence in research and patient care, they strive to make significant advancements in understanding and managing pulmonary arterial hypertension.
In Kansas City, the University of Kansas Medical Center has six ongoing studies aimed at improving outcomes for patients with pulmonary arterial hypertension. They are committed to finding innovative solutions that can enhance quality of life and prolong survival rates among those affected by this rare condition. Meanwhile, Vanderbilt University Medical Center located in Nashville shares a similar dedication as they too conduct six active clinical trials specifically addressing pulmonary arterial hypertension. Their efforts contribute significantly to unraveling new insights into this complex disease.
Finally, The Ohio State University Wexner Medical Center located in Columbus rounds out our list with five currently ongoing clinical trials focusing on pulmonary arterial hypertension. Their commitment demonstrates their passion for advancing medical knowledge surrounding this condition while striving towards more effective treatments.
Though these hospitals have yet to complete any past trials specific to pulmonary arterial hypertension (PAH), their current endeavors send an encouraging message that researchers across multiple prestigious institutions are actively working towards improving outcomes for PAH patients worldwide through groundbreaking investigations
Which are the best cities for pulmonary arterial hypertension clinical trials?
When it comes to pulmonary arterial hypertension clinical trials, several cities have emerged as leading centers for research and development. Los Angeles, California leads the way with 29 active trials exploring treatments like Ralinepag, AV-101, and Treprostinil Inhalation Powder. Boston, Massachusetts closely follows with 23 ongoing studies focused on innovative approaches such as Ralinepag and Sotatercept. New york, New York also plays a significant role in advancing treatment options with 18 active trials investigating therapies like GB002 (seralutinib) and Macitentan 75 mg. Additionally, Cincinnati, Ohio and Houston, Texas both contribute to the field of pulmonary arterial hypertension research through their respective 15 active trials. These cities offer individuals living with this condition access to cutting-edge clinical trials that pave the way for advancements in care and provide hope for improved outcomes.
Which are the top treatments for pulmonary arterial hypertension being explored in clinical trials?
Pulmonary arterial hypertension (PAH) is a challenging condition, but ongoing clinical trials bring hope for new treatments. The top contenders in these trials include:
- Selexipag: Being explored in 8 active PAH trials and has been listed since 2015.
- Riociguat: Under investigation in 6 current studies for PAH, with its first listing dating back to 2007.
- Macitentan: Engaged in 4 active PAH trials and has been part of the research landscape since 2009.
These cutting-edge therapies are paving the way towards improved management and outcomes for individuals living with pulmonary arterial hypertension.
What are the most recent clinical trials for pulmonary arterial hypertension?
Exciting advancements are being made in the field of pulmonary arterial hypertension (PAH) through recent clinical trials. One notable trial investigates the efficacy of hyperpolarized 129Xe, offering potential insights into new treatment approaches for PAH patients. Another study focuses on healthy volunteers to gain a better understanding of this condition and improve diagnostic techniques. Additionally, researchers are evaluating the use of Treprostinil Palmitil Inhalation Powder (TPIP) in both Phase 2 and Phase 3 trials, aiming to provide an innovative therapeutic option for individuals with PAH. Furthermore, investigations also extend to pediatric populations aged ≥1 to <18 years old as they strive to enhance care tailored specifically towards younger patients. Lastly, a promising Phase 3 trial explores the potential benefits of low-dose AV-101 for those living with PAH. These cutting-edge studies offer hope for improved treatments that can positively impact the lives of individuals affected by PAH.
What pulmonary arterial hypertension clinical trials were recently completed?
Several recent clinical trials have made significant progress in the field of pulmonary arterial hypertension, offering hope for patients with this challenging condition. Notably, a trial conducted by United Therapeutics Corporation investigating Ralinepag reached completion in December 2021. Another important study sponsored by Actelion Pharmaceuticals explored the efficacy of Macitentan and concluded in September 2021. Furthermore, Merck Sharp & Dohme Corp completed their trial evaluating Vericiguat as a potential treatment option for pulmonary arterial hypertension in May 2021. These advancements represent promising steps forward in improving outcomes and quality of life for individuals living with this debilitating disease.